GFAP and Alzheimer disease: We found that the area expressing GFAP, which marks activated astrocytes, was larger in the hippocampus of the AD group compared to the WT group, and that astrocyte activation was significantly suppressed in the anserine-treated AD group (**p < 0.01) (Fig. 6).